BACKGROUND: Adherence of 95% or more to unboosted protease regimens is required for optimal virologic suppression in HIV-1-infected patients. Whether the same is true for nonnucleoside reverse transcriptase inhibitor (NNRTI)-based therapy is unclear. OBJECTIVE: To assess the relationship between adherence to NNRTI-based therapy and viral load in treatment-naive patients. DESIGN: Observational cohort study. SETTING: Private-sector HIV and AIDS disease management program in South Africa. PATIENTS: 2821 adults infected with HIV who began NNRTI-based therapy between January 1998 and March 2003 (2764 patients [98%] were enrolled after December 2000). MEASUREMENTS: Adherence was assessed by monthly pharmacy claims. The primary end point was sustained viral load suppression (<400 copies/mL) in 100% of recorded viral load measurements throughout follow-up. Secondary end points included time to initial viral load suppression and time to subsequent virologic failure (>400 copies/mL). RESULTS: The median follow-up period was 2.2 years (interquartile range, 1.7 to 2.7 years). The proportion of patients with sustained viral load suppression ranged from 13% (41 of 325 patients) in patients who filled less than 50% of antiretroviral drug prescriptions to 73% (725 of 997 patients) in those who filled 100% of antiretroviral drug prescriptions. Each 10% increase in pharmacy claim adherence greater than 50% was associated with a mean absolute increase of 0.10 in the proportion of patients with sustained virologic suppression (P < 0.001). Predictors for shorter time to virologic failure after initial suppression in multivariable Cox regression included CD4+ T-cell counts of 0.50 x 10(9) cells/L or less (hazard ratio, 1.60 [95% CI, 1.22 to 2.10] vs. CD4+ T-cell counts >0.20 x 10(9) cells/L), baseline viral load greater than 10(5) copies/mL (hazard ratio, 1.39 [CI, 1.14 to 1.70]), nevirapine-based regimen (hazard ratio, 1.43 [CI, 1.16 to 1.75]), and low pharmacy claim adherence (hazard ratio, 1.58 [CI, 1.48 to 1.69], per 10% decrease in adherence to 50%). LIMITATIONS: Observational study with adherence stratification at study end and lack of standardized timing for outcome measurement. CONCLUSION: Virologic outcomes improve in a linear dose-response manner as adherence to NNRTI-based regimens increases beyond 50%.
BACKGROUND: Adherence of 95% or more to unboosted protease regimens is required for optimal virologic suppression in HIV-1-infectedpatients. Whether the same is true for nonnucleoside reverse transcriptase inhibitor (NNRTI)-based therapy is unclear. OBJECTIVE: To assess the relationship between adherence to NNRTI-based therapy and viral load in treatment-naive patients. DESIGN: Observational cohort study. SETTING: Private-sector HIV and AIDS disease management program in South Africa. PATIENTS: 2821 adults infected with HIV who began NNRTI-based therapy between January 1998 and March 2003 (2764 patients [98%] were enrolled after December 2000). MEASUREMENTS: Adherence was assessed by monthly pharmacy claims. The primary end point was sustained viral load suppression (<400 copies/mL) in 100% of recorded viral load measurements throughout follow-up. Secondary end points included time to initial viral load suppression and time to subsequent virologic failure (>400 copies/mL). RESULTS: The median follow-up period was 2.2 years (interquartile range, 1.7 to 2.7 years). The proportion of patients with sustained viral load suppression ranged from 13% (41 of 325 patients) in patients who filled less than 50% of antiretroviral drug prescriptions to 73% (725 of 997 patients) in those who filled 100% of antiretroviral drug prescriptions. Each 10% increase in pharmacy claim adherence greater than 50% was associated with a mean absolute increase of 0.10 in the proportion of patients with sustained virologic suppression (P < 0.001). Predictors for shorter time to virologic failure after initial suppression in multivariable Cox regression included CD4+ T-cell counts of 0.50 x 10(9) cells/L or less (hazard ratio, 1.60 [95% CI, 1.22 to 2.10] vs. CD4+ T-cell counts >0.20 x 10(9) cells/L), baseline viral load greater than 10(5) copies/mL (hazard ratio, 1.39 [CI, 1.14 to 1.70]), nevirapine-based regimen (hazard ratio, 1.43 [CI, 1.16 to 1.75]), and low pharmacy claim adherence (hazard ratio, 1.58 [CI, 1.48 to 1.69], per 10% decrease in adherence to 50%). LIMITATIONS: Observational study with adherence stratification at study end and lack of standardized timing for outcome measurement. CONCLUSION: Virologic outcomes improve in a linear dose-response manner as adherence to NNRTI-based regimens increases beyond 50%.
Authors: Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris Journal: AIDS Date: 2010-07-17 Impact factor: 4.177
Authors: Vincent Lo Re; Valerie Teal; A Russell Localio; Valerianna K Amorosa; David E Kaplan; Robert Gross Journal: Ann Intern Med Date: 2011-09-20 Impact factor: 25.391
Authors: M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Jean B Nachega; Richard E Chaisson; Rene Goliath; Anne Efron; Mohammad A Chaudhary; Malathi Ram; Chelsea Morroni; Hennie Schoeman; Amy R Knowlton; Gary Maartens Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Noah C Godwin; James H Willig; Christa R Nevin; Hui-Yi Lin; Jeroan Allison; Kathy Gaddis; Jennifer Peterson; Michael S Saag; Michael J Mugavero; James L Raper Journal: Health Serv Res Date: 2011-01-06 Impact factor: 3.402
Authors: Patricia Sweeney; Lytt I Gardner; Kate Buchacz; Pamela Morse Garland; Michael J Mugavero; Jeffrey T Bosshart; R Luke Shouse; Jeanne Bertolli Journal: Milbank Q Date: 2013-07-08 Impact factor: 4.911
Authors: David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: Mahnaz R Charania; Khiya J Marshall; Cynthia M Lyles; Nicole Crepaz; Linda S Kay; Linda J Koenig; Paul J Weidle; David W Purcell Journal: AIDS Behav Date: 2014-04
Authors: Lynn T Matthews; Heather B Ribaudo; Angela Kaida; Kara Bennett; Nicholas Musinguzi; Mark J Siedner; Jerome Kabakyenga; Peter W Hunt; Jeffrey N Martin; Yap Boum; Jessica E Haberer; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731